

Xian-Ping Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9064018/publications.pdf>

Version: 2024-02-01

6
papers

188
citations

1684188
5
h-index

1872680
6
g-index

6
all docs

6
docs citations

6
times ranked

225
citing authors

#	ARTICLE	IF	CITATIONS
1	Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas. <i>Journal of Oncology</i> , 2021, 2021, 1-15.	1.3	10
2	Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). <i>Science Bulletin</i> , 2021, 66, 1571-1580.	9.0	22
3	Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). <i>Science Bulletin</i> , 2021, 66, 1581-1590.	9.0	16
4	Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPAR α . <i>PPAR Research</i> , 2017, 2017, 1-16.	2.4	30
5	Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 483-491.	5.6	56
6	The PPAR α / β dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. <i>British Journal of Pharmacology</i> , 2006, 148, 610-618.	5.4	54